Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics, Inc. (MAZE) Healthcare & Pipeline Overview

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in small molecule precision medicines for renal, cardiovascular, and metabolic diseases, including obesity. Their lead programs, MZE829 and MZE782, are currently in Phase II and Phase I clinical trials, respectively, positioning them in a competitive landscape of targeted therapeutics.

What Is the Investment Thesis for MAZE?

Maze Therapeutics, Inc. presents a notable research candidate within the biotechnology sector, driven by its focus on precision medicines targeting genetically defined diseases. The company's lead program, MZE829, targeting APOL1-mediated kidney disease, has the potential to address a significant unmet need in a patient population with limited treatment options. Positive Phase II clinical trial results for MZE829 could serve as a major catalyst, driving significant value. Similarly, the advancement of MZE782 through Phase I clinical trials for chronic kidney disease offers further upside potential. However, the company's high beta of 5.16 indicates significant volatility. Success hinges on clinical trial outcomes and regulatory approvals, making it a high-risk, high-reward investment.

Based on FMP financials and quantitative analysis

MAZE Key Highlights

• Market capitalization of $1.79B reflects investor confidence in Maze Therapeutics' pipeline and precision medicine approach.
• MZE829, the lead program, is in Phase II clinical trials, targeting APOL1 kidney disease, a significant milestone in its development.
• MZE782, another key program, is in Phase I clinical trials for chronic kidney disease, expanding the company's therapeutic focus.
• The company's focus on small molecule precision medicines aims to provide more targeted and effective treatments with fewer side effects.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development to advance its pipeline.

Who Are MAZE's Competitors?

MAZE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MAZE's Key Strengths?

• Strong focus on precision medicine.
• Proprietary small molecule drug candidates.
• Clinical-stage pipeline with Phase II and Phase I assets.
• Experienced management team.

What Are MAZE's Weaknesses?

• Reliance on clinical trial outcomes.
• High cash burn rate associated with drug development.
• Competition from larger pharmaceutical companies.
• Limited commercialization experience.

What Could Drive MAZE Stock Higher?

• Phase II clinical trial results for MZE829 in APOL1 kidney disease (expected in 2027).
• Advancement of MZE782 into Phase II clinical trials for chronic kidney disease (expected in 2028).
• Potential for strategic partnerships with pharmaceutical companies.
• Expansion of pipeline into new therapeutic areas.

What Are the Key Risks for MAZE?

• Negative return on equity (-36.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for MZE829 or MZE782.
• Regulatory setbacks in obtaining FDA approval.
• Competition from existing therapies and other companies developing precision medicines.
• High cash burn rate associated with drug development.
• Patent challenges to Maze Therapeutics' intellectual property.

What Are the Growth Opportunities for MAZE?

• Expansion of MZE829 into Additional APOL1-Mediated Diseases: Beyond its current focus on APOL1 kidney disease, MZE829 has the potential to address other diseases mediated by APOL1, such as focal segmental glomerulosclerosis (FSGS). The market for FSGS treatment is estimated to reach $1.5 billion by 2030, providing a significant growth opportunity for Maze Therapeutics if MZE829 proves effective in this indication. This expansion could begin following successful Phase II trials, potentially by 2028.
• Advancement of MZE782 into Later-Stage Clinical Trials: The successful completion of Phase I clinical trials for MZE782 in chronic kidney disease (CKD) would pave the way for Phase II and Phase III trials. The global CKD market is projected to reach $20 billion by 2027, offering a substantial market opportunity for Maze Therapeutics. Positive data from these trials could lead to regulatory approval and commercialization by 2030.
• Strategic Partnerships with Pharmaceutical Companies: Maze Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its pipeline assets. These partnerships could provide access to additional funding, expertise, and resources, accelerating the development and commercialization process. Such partnerships could be initiated as early as 2027, following positive clinical trial data.
• Expansion into New Therapeutic Areas: Maze Therapeutics could leverage its expertise in precision medicine to expand into new therapeutic areas beyond renal, cardiovascular, and metabolic diseases. This could include exploring opportunities in oncology or neurology, where genetically defined diseases are prevalent. The market for precision oncology is expected to reach $100 billion by 2028, presenting a significant growth opportunity. This expansion could begin by 2029, following the establishment of a strong track record in its current focus areas.
• Development of Companion Diagnostics: The development of companion diagnostics to identify patients who are most likely to benefit from Maze Therapeutics' therapies could enhance the effectiveness and adoption of its products. Companion diagnostics can help to personalize treatment and improve patient outcomes. The market for companion diagnostics is projected to reach $8 billion by 2027. Maze could begin developing companion diagnostics for MZE829 and MZE782 by 2027, aligning with the advancement of these programs through clinical trials.

What Opportunities Does MAZE Have?

• Expansion into new therapeutic areas.
• Strategic partnerships with pharmaceutical companies.
• Development of companion diagnostics.
• Potential for breakthrough therapies in genetically defined diseases.

What Threats Does MAZE Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from existing therapies.
• Patent challenges.

What Are MAZE's Competitive Advantages?

• Proprietary small molecule drug candidates with patent protection.
• Focus on precision medicine targeting specific genetic drivers of disease.
• Clinical trial data demonstrating safety and efficacy.
• Expertise in renal, cardiovascular, and metabolic diseases.

What Does MAZE Do?

Maze Therapeutics, Inc., founded in 2017 and based in South San Francisco, California, is a clinical-stage biopharmaceutical company dedicated to developing small molecule precision medicines. Originally named Modulus Therapeutics, Inc., the company rebranded in September 2018 to Maze Therapeutics, Inc. The company focuses on addressing unmet needs in renal, cardiovascular, and related metabolic diseases, as well as obesity. Maze's approach involves identifying and targeting specific genes and pathways to create therapies that are more effective and have fewer side effects than traditional treatments. Their lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1 (APOL1), which is currently in Phase II clinical trial for patients with APOL1 kidney disease. Additionally, MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, is in Phase I clinical trial for the treatment of chronic kidney disease. These programs highlight Maze's commitment to addressing significant medical needs with innovative, targeted therapies. With a team of 125 employees, Maze Therapeutics is advancing its pipeline and seeking to transform the treatment landscape for complex diseases.

What Products and Services Does MAZE Offer?

• Develop small molecule precision medicines.
• Target renal diseases such as APOL1 kidney disease.
• Address cardiovascular and related metabolic diseases.
• Develop treatments for obesity.
• Conduct Phase II clinical trials for MZE829, an APOL1 inhibitor.
• Conduct Phase I clinical trials for MZE782, an SLC6A19 inhibitor.

How Does MAZE Make Money?

• Develop proprietary small molecule drugs targeting specific genetic pathways.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA for commercialization.
• Potentially partner with larger pharmaceutical companies for manufacturing and distribution.

What Industry Does MAZE Operate In?

Maze Therapeutics operates in the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for precision medicines is growing, driven by advancements in genomics and personalized healthcare. Companies like Maze are focusing on developing targeted therapies that address specific genetic drivers of disease. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in specific disease areas. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.

Who Are MAZE's Key Customers?

• Patients with APOL1-mediated kidney disease.
• Patients with chronic kidney disease.
• Individuals with cardiovascular and related metabolic diseases.
• People with obesity.

ROE -37%Key Financial Metrics

Return on equity for Maze Therapeutics, Inc. stands at -36.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.5%, the inverse of the P/E and a quick read on earnings relative to price.

Maze Therapeutics, Inc. (MAZE) Valuation Context

Valued at $1.79B, MAZE is classified as a small-cap stock. Relative to its peer group, MAZE's quantitative score of 20/100 is below the peer average of 78/100.

Company Profile

Maze Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Jason V. Coloma. MAZE has traded publicly since 2025.

F-Score 3/9Financial Health

Maze Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.71 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Maze Therapeutics, Inc. revenue of about $22.0M for fiscal 2026, with EPS near $-2.73. The estimate reflects 8 contributing analysts.

MAZE Financials

MAZE Latest News

MAZE Analyst Consensus

MAZE MoonshotScore

Maze Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources